PHAXIAM Therapeutics S.A. Euronext Paris

Equities

PHXM

FR0011471135

Biotechnology & Medical Research

Real-time Euronext Paris 08:41:49 2024-03-28 am EDT 5-day change 1st Jan Change
2.99 EUR -0.17% Intraday chart for PHAXIAM Therapeutics S.A. +2.57% -35.00%
Chart PHAXIAM Therapeutics S.A.
More charts
Following the merger with PHERECYDES in June 2023, ERYTECH Pharma S.A. has changed its corporate name to PHAXIAM Therapeutics S.A. The new group is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, responsible for many serious infections. The company relies on an innovative approach based on the use of phages, natural bacteria-killing viruses. PHAXIAM Therapeutics S.A. is developing a portfolio of phages targeting 3 of the most resistant and dangerous bacteria, which alone account for more than two-thirds of resistant nosocomial infections: Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.995 EUR
Average target price
9.6 EUR
Spread / Average Target
+220.53%
Consensus